Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 51Urinary Bladder Neoplasms 15Breast Neoplasms 10Carcinoma, Renal Cell 8Colorectal Neoplasms 7Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Non-Small-Cell Lung 4Motor Activity 3Colonic Neoplasms 3Urologic Neoplasms 2Urologic Diseases 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Rectal Neoplasms 2Prostate Cancer Metastatic 2Neoplasms by Site 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Kidney Failure, Chronic 2Esophageal Neoplasms 2COVID-19 2Breast Neoplasms, Male 2

Interventions

padeliporfin 5Mitomycin 3pembrolizumab 2alectinib 2Standard of Care 2Pluvicto 2Nivolumab 2Cisplatin 2Abiraterone Acetate 2valrubicin 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1osimertinib 1onapristone 1olaparib 1gallium 68 PSMA-11 1enzalutamide 1enfortumab vedotin 1darolutamide 1cobimetinib 1apalutamide 1abiraterone 1Therapeutics 1Taxes 1Sunitinib 1Radiation Dose Hypofractionation 1Pemetrexed 1Paclitaxel 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Standard of Care × Genitourinary × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡